. Highlighted was the development of biomarkers to more rapidly and/or more efficiently determine the benefit risk profile of a new therapy. Potential uses of biomarkers that were listed included genomic tests to identify patients at high risk for serious toxicity, markers of drug metabolism to individualize drug dosage, and new imaging techniques to assess treatment efficacy. In addition, the qualification of new surrogate endpoints, a subset of biomarkers targeted at later-phase clinical trials, was identified as an important area to drive more rapid drug development. As recognized by the FDA, the use of surrogate endpoints holds great promise for improving the efficiency in clinical research. Given the pressing need for new pediatric therapies, incorporating surrogate endpoints could be a significant aid to accelerate development. However, the use of surrogate endpoints has been controversial; with the unique aspects of pediatric research, it is vital that surrogate endpoints be used appropriately, and potentially more frequently, in this population. In this chapter, we will examine the use of surrogate endpoints in clinical research in general and the role that they can play in pediatric research in particular.
Definition of Surrogate Endpoint
Although surrogate endpoints have been present in the scientific debate for over two decades, varying definitions have been used, the earliest one going back to the duration and complexity of the trial. However, often, the most sensitive and relevant clinical endpoint, the so-called "true" endpoint, can pose severe challenges for evaluation. For example, the use of clinical endpoints such as survival in newly diagnosed patients with breast cancer, or short-term mortality in patients following acute myocardial infarction (a relatively infrequent event) would result in large, long, and expensive trials. An effective strategy in these situations is to identify alternative endpoints, or surrogates, that are less costly to be measured, are more conveniently assessed, or occur earlier or more frequently than the true clinical endpoint.
In the 1980s, with the alarming rise in HIV infections and AIDS-related deaths, the approval process of new therapies relying on traditional clinical outcomes was questioned. The scientific and regulatory "gold-standard" for a clinical trial endpoint was one where distinct clinical impact could be shown. In the case of demonstrating a treatment effect on HIV infections, this required assessing the clinical outcomes of either prevention of progression to AIDS or increased overall survival. However, the time and cost associated with trials using these outcome measures were unacceptable given the epidemic of HIV infection. In response to the demand for more rapid approval, the accelerated approval provisions were added to the US new drug regulations Regulatory authorization allowing approval based on surrogate endpoints coupled with the need to reduce the ever-rising costs of developing new therapies led to an increased use of surrogate endpoints as the regulatory basis for approval 8 . Examples include CD4 + T-lymphocyte counts (CD4) in HIVinfected subjects rather than progression to AIDS or death, cholesterol levels in lieu of occurrence of myocardial infarction, and tumor response rates instead of reoccurrence.
Controversy With Surrogate Endpoints
In spite of the potential advantages, the use of surrogate endpoints has been controversial due to several dramatic failures of a surrogate endpoint to adequately substitute for a clinical endpoint 9 . During the early 1990s, FDA approved the drugs encainide and flecainide after effective suppression of ventricular arrhythmias was demonstrated. It was believed that since arrhythmia is associated with a four-fold increase in sudden death following myocardial infarction, these drugs would reduce the death rate after myocardial infarction.
Following approval, however, results from the Cardiac Arrhythmia Suppression Trial (CAST) 10 , showed that the death rate among subjects treated with encainide and flecainide was more that twice that observed in the placebo subjects. In addition, relying on surrogate endpoints in smaller clinical trials has raised concerns about detecting safety issues that can only be detected in large randomized trials 11 .
In contrast, reliance on a surrogate endpoint may fail to show the true effect of a new therapy. For example, the evaluation of interferon gamma on recurrent infections in patients with chronic granulomatous disease, a surrogate endpoint for phagocytic function, did not show a therapeutic effect; but clinical benefit was demonstrated by substantial reduction in serious infections 4, 12 .
These failures in the use of surrogate endpoints for evaluating therapeutic effect were fundamentally due to the misconception that an association between a true clinical endpoint and an observed biomarker is sufficient to declare a biomarker as a surrogate. The mere existence of an association between a candidate surrogate endpoint and the true endpoint is not sufficient for using the former as a surrogate: "a correlate does not a surrogate make" 9 .
Although an association between a potential and true clinical endpoint is desirable, what is required is that the effect of the treatment on the surrogate endpoint reliably predict the effect on the true endpoint. Unfortunately, partly owing to the lack of appropriate methodology, this condition was not met in the early attempts to use surrogate endpoints and, consequently, negative opinions about the use of surrogates in the evaluation of treatment efficacy have been voiced 9, 13, 14 .
Why Continue with Surrogate Endpoints?
In Surrogate endpoints also can be used for early detection of safety issues that could point to toxicity problems of a new therapy. The duration and size of clinical trials designed to evaluate efficacy of a new drug are often insufficient to detect rare adverse events or events that occur after prolonged therapy 17, 18 . The use of surrogate endpoints in this context of toxicity-related clinical endpoints might allow one to obtain information about such effects even during the clinical testing phase.
Further, new discoveries in medicine and biology are creating an exciting range of possibilities for the development of many potentially effective treatments for a particular disease. This unquestionably is an achievement, but in turn it creates a challenge to rapidly evaluate a large number of new, promising treatments.
Surrogate endpoints in the development program can offer an efficient route.
Finally, shortening the duration of a clinical trial using a surrogate endpoint not only can decrease the cost of the evaluation process, but also can limit potential problems with non-compliance and missing data, thereby increasing research effectiveness and reliability 19, 20 . Benefits to the subject are also obvious in terms of reduced time and the number of potential studies related to the clinical trial burden.
The potential of surrogate endpoints to accelerate and improve the quality of clinical trials is clear. However, early experiences also demonstrate that only thoroughly evaluated surrogate endpoints should be used. The following section discusses this issue further.
Statistical Evaluation of Surrogate Endpoints
Thus, while some of the past failures have led a number of researchers to the conclusion that surrogate endpoints should be avoided altogether, practice has clearly shown that sometimes surrogate endpoints are the only reasonable and . A perfect surrogate endpoint, as described by Prentice, can be represented as:
where X is the treatment, S is the surrogate endpoint and, and T is the true clinical outpoint. In this paradigm, the surrogate endpoint mediates all of the effect of the treatment on the true clinical endpoint. Prentice proposed four operational criteria to validate a proposed surrogate endpoint:
1. treatment (X) has a significant effect on the surrogate endpoint (S);
2. treatment (X) has a significant impact on the true endpoint (T);
3. the surrogate endpoint (S) has a significant impact on the true endpoint (T);
4. the full effect of treatment (X) upon the true endpoint (t) is captured by the surrogate (S).
Although intuitively appealing, much debate ensued, for the criteria set out by
Prentice are not straightforward to verify 21, 22 . The fourth criterion is particularly challenging, as it requires that the surrogate must explain 100% of the treatment effect on the true clinical endpoint. In addition, Prentice's criteria could only be applied to binary endpoints (e.g., success versus failure) 19, 23 .
Freedman supplemented Prentice's approach by introducing the term proportion of treatment explained (PE), aimed at measuring the proportion of the treatment effect mediated by the surrogate 22 . This proposal was important as it shifted the interest in the validation of surrogate endpoints from significance testing to estimation of the treatment effect explained by the surrogate. However, properties of the PE made it difficult to reliably estimate 19, 23 , e.g., the denominator of the proportion explained (the effect of treatment on the true clinical endpoint)
usually cannot be estimated with precision 24 . Moreover, and fundamentally, the PE is flawed in the sense that it is not restricted to the unit interval. Attempting to further refine this approach, Buyse and Molenberghs This meta-analytic method fully captures both dimensions of validation of a proposed surrogate. Nevertheless, a question that immediately arises in this setting is which of these two dimensions is the most important one in practice.
There is no single answer to this question but will depend on the context. For a trialist who wants to use the surrogate to predict the treatment effect on the true endpoint, the trial dimension will clearly be the most interesting one. However, for a treating physician who has observed a tumor response in a specific patient and wants to know how this can predict the survival of the patient, the individual dimension will be most useful. 30, 31 .
Though this approach is based on the single-trial setting and some strong assumptions are required, it appears to be a promising line of research, especially to evaluate potential surrogates in the initial stages of development when little information about the surrogate is available.
With the advent of new biomarkers and the increase in understanding of disease mechanism, there will be a continuing need for developing new statistical models for testing the validity of new proposed surrogates. To best assist in the evaluation of a biomarker as a potential surrogate endpoint, a statistical framework must be established during all stages of therapeutic development including the exploratory phases of a new compound 32 .
Surrogate Endpoints in Pediatric Trials
The Several statins (e.g., lovastatin, atorvastatin, simvastain, and pravastatin) have been approved for familial hypercholesterolemia in pediatric patients. Similar to the approval process for these medications in adults, efficacy was based on the surrogate endpoint of lowering LDL cholesterol. Although pediatric patients with this diagnosis are at greater risk for coronary heart disease (CHD), no studies have examined the long-term safety of statin therapy or decrease in CHD morbidity and mortality with chronic exposure.
Vaccines are difficult to assess based on true clinical outcome due to the long duration of observation and, for some indications, the rarity of infection.
Vaccines can be approved using a responder analysis demonstrating an immune response, e.g., seroconversion in those subjects initially seronegative or the maintenance of an increase above pre-vaccination concentrations in subjects who were initially seroposititive. The FDA will generally require Phase 4 commitments to study adverse effects and long-term monitoring is required to ensure adequate protection. The debate over the association of autism and childhood immunizations highlights the difficulty in fully assessing the benefit risk profile in pediatrics using a short-term surrogate endpoint. Even if true developmental safety issues exist, they can take years to assess.
As directed in the 2002 guidance for accelerated approval of antiretroviral drugs 41 , the five pediatric exclusivity approvals and one PREA approval to treat HIV infections have been based on the surrogate endpoints of HIV-1 RNA levels < 400 copies/ml and increases in CD4 counts. Substantial scientific work has focused on HIV-1 RNA levels and CD4 counts as surrogate endpoints, including in-depth meta-analyses aimed at validating these measures as useful surrogates 42 . Such meta-analyses have focused on adult patients and it is not known whether these surrogate endpoints will prove reliable predictors for longterm outcome in the pediatric population treated early in life.
As .
Concluding Remarks
In this chapter, we have described the history of surrogate endpoints, the early misconceptions in assessing a proposed surrogate, and the development of statistical methodologies to accurately evaluate, in a quantitative fashion, surrogate endpoints. Surrogate endpoints in pediatric trials offer potential benefits in reducing the time to evaluation of a new therapy, as well as the number of exposed patients, thereby allowing for less invasive measurements, and collecting developmentally appropriate measures.
With the hoped for increase in pediatric clinical trials, a need for surrogate endpoints will likely increase as well. We must proceed cautiously to ensure that the selection of surrogates is based on sound scientific rationale. Noted failures of surrogate endpoints to adequately assess treatment effect in adults must not be repeated in pediatric clinical trials. The concern over inadequately assessing Page 19 of 24 the benefit risk ratio with a surrogate endpoint is of even greater concern in the pediatric population. Close collaboration between basic scientists, clinicians, and statisticians can facilitate the appropriate use of surrogate endpoints. Beginning early in the development cycle of a new drug, not only should emphasis be placed on identifying potential biomarkers associated with the proposed mechanism of action, but biomarkers that reflect developmental and chronological differences within the target patient population. Biomedical research will inevitably lead to new biomarkers that must be evaluated, and statistical models must be developed to assess new disease mechanisms and the association of surrogate endpoints. Trial designs should facilitate the evaluation of proposed surrogates, including standardizing collection methods and frequency of biomarker measurements to allow for across-study analyses to be performed. Careful and sound scientific methods will ensure that surrogate endpoints can effectively be use to assess new therapies in children.
